Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: Potential prospects for combined targeted therapeutics (review)

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 393-406

  Zimonjic, Drazen B ^a   Popescu, Nicholas C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

DLC1; Liver cancer; MYC; Oncogene; Targeted therapy; Tumor suppressor

Indexed keywords

DLC1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CARCINOMA CELL; CELL GROWTH; CHROMOSOME 8P; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE CONTROL; GENE DELETION; GENE MUTATION; GENE SILENCING; HETEROZYGOSITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; METAPHASE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GTPASE-ACTIVATING PROTEINS; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84863574716     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1474     Document Type: Review

References (171)

1. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
2. Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
3. Rowley JD: Ph1-positive leukaemia, including chronic myelogenous leukaemia. Clin Haematol 9: 55-86, 1980.
4. Kraus MH, Popescu NC, Amsbaugh SC and King CR: Overexpression of the EGF receptor-related protooncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605-610, 1987.
5. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007. (Pubitemid 46273572)
6. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ and Herman JG: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361-6369, 2006.
7. Richon VM, Garcia-Vargas J and Hardwick JS: Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280: 201-210, 2009.
8. Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellullar carcinoma. Nat Genet 31: 339-346, 2002. (Pubitemid 35154440)
9. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinima incidence, mortality and survival trends in United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
10. Jones RG and Thompson CB: Tumor suppressor and cell metabolism: a recipe for cancer growth. Genes Dev 23: 537-548, 2009.
11. Keck CL, Zimonjic DB, Yuan BZ, Thorgeirsson SS and Popescu NC: Nonrandom breakpoints of unbalanced chromosome translocations in human hepatocellular carcinoma cell lines. Cancer Genet Cytogenet 111: 37-44, 1999. (Pubitemid 29214333)
12. Zimonjic DB, Keck CL, Thorgeirsson SS and Popescu NC: Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology 29: 1208-1214, 1999. (Pubitemid 29168756)
13. Popescu NC: Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett 192: 1-17, 2003.
14. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009.
15. Simon D, Knowles B and Weith A: Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas. Oncogene 6: 765-770, 1991. (Pubitemid 21924149)
16. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC and Chen DS: Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res 54: 4188-4192, 1994.
17. Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ and Thorgeirsson SS: Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 69: 4059-4066, 2009.
18. Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS and Popescu NC: Alterations of FHIT gene in human hepatocellular carcinoma. Cancer Res 60: 1049-1053, 2000. (Pubitemid 30129544)
19. Imreh S, Klein G and Zabarovsky ER: Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer 38: 307-321, 2003. (Pubitemid 37466930)
20. Zhou X, Popescu NC, Klein G and Imreh S: The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma. Cancer Genet Cytogenet 177: 6-15, 2007. (Pubitemid 47211290)
21. Zimonjic DB, Zhou X, Lee JS, Ullmannova-Benson V, Tripathi V, Thorgeirsson SS and Popescu NC: Acquired genetic and functional alterations associated with transforming growthfactor beta type I resistance in Hep3B human hepatocellular carcinoma cell line. J Cell Mol Med 13: 3985-3992, 2009.
22. Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M and Aldaz CM: WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100: 101-110, 2003. (Pubitemid 37467796)
23. Park SW, Ludes-Meyers J, Zimonjic DB, Durkin ME, Popescu NC and Aldaz CM: Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 91: 753-759, 2004. (Pubitemid 39141636)
24. Yuan BZ, Zhou X, Zimonjic DB, Durkin ME and Popescu NC: Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma. J Mol Diagn 5: 48-53, 2003. (Pubitemid 36193000)
25. Zimonjic DB, Durkin ME, Keck-Waggoner CL, Park SW, Thorgeirsson SS and Popescu NC: SMAD5 gene expression, re arrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma. Neoplasia 5: 390-396, 2003. (Pubitemid 37475647)
26. Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, Miyaki M, Monden M and Nakamura Y: Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 7: 152-157, 1993. (Pubitemid 23194424)
27. Pineau P, Nagai H, Prigent S, Wei Y, Gyapay G, Weissenbach J, Tiollais P, Buendia MA and Dejean A: Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene 18: 3127-3134, 1999. (Pubitemid 29261233)
28. Qin LX, Tang ZY, Sham JS, Ma ZC, Ye SL, Zhou XD, Wu ZQ, Trent JM and Guan XY: The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 59: 5662-5665, 1999.
29. Chan KL, Lee JM, Guan XY, Fan ST and Ng IO: High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer 94: 3179-3185, 2002. (Pubitemid 34670501)
30. Kahng YS, Lee YS, Kim BK, Park WS, Lee JY and Kang CS: Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma. J Gastroenterol Hepatol 18: 430-436, 2003. (Pubitemid 36549554)
31. Pang JZ, Qin LX, Ren N, Hei ZY, Ye QH, Jia WD, Sun BS, Lin GL, Liu DY, Liu YK and Tang ZY: Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma. Clin Cancer Res 13: 7363-7369, 2007.
32. Yam JW, Wong CM and Ng IO: Molecular and functional genetics in hepatocellular carcinoma. Front Biosci (Schol Ed) 2: 117-134, 2010.
33. Birnbaum D, Adélaïde J, Popovici C, Charafe-Jauffret E, Mozziconacci MJ and Chaffanet M: Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncol 4: 639-642, 2003. (Pubitemid 37258407)
34. Popescu NC: Fragile sites and cancer genes on the short arm of chromosome 8. Lancet Oncol 5: 77, 2004.
35. Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M and Nakamura Y: Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. Oncogene 10: 891-895, 1995.
36. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and PopescuNC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 58: 2196-2199, 1998. (Pubitemid 28232908)
37. Yan J, Yu Y, Wang N, Chang Y, Ying H, Liu W, He J, Li S, Jiang W, Li Y, Liu H, Wang H and Xu Y: LFIRE-1/ HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene 23: 1939-1949, 2004. (Pubitemid 38445420)
38. Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY and Lin YW: Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 107: 579-590, 2006.
39. Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY and Han ZG: Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 7: 126, 2007.
40. Lei KF, Wang YF, Zhu XQ, Lu PC, Sun BS, Jia HL, Ren N, Ye QH, Sun HC, Wang L, Tang ZY and Qin LX: Identification of MSRA gene on chromosome 8p as a candidate metastasis suppressor for human hepatitis B virus-positive hepatocellular carcinoma. BMC Cancer 7: 172, 2007.
41. Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, Wang YP, Xiao HS and Han ZG: Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest 120: 223-241, 2010.
42. Finch PW, He X, Kelley MJ, Uren A, Schaudies P, Popescu NC, Rudicoff S, Aaronson SA, Varmus HE and Rubin JS: Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA 94: 6670-6675, 1997.
43. Rubin JS, Barshishat-Kupper M, Feroze-Merzoug F and Xi ZF: Secreted WNT antagonists as tumor suppressors: pro and con. Front Biosci 11: 2093-2105, 2006. (Pubitemid 43822543)
44. Saini S, Liu J, Yamamura S, Majid S, Kawakami K, Hirata H and Dahiya R: Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas. Cancer Res 69: 6815-6822, 2009.
45. Kawamoto K, Hirata H, Kikuno N, Tanaka Y, Nakagawa M and Dahiya R: DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 123: 535-542, 2008. (Pubitemid 351898410)
46. Thompson MD and Monga SP: WNT/beta-catenin signaling in liver health and disease. Hepatology 45: 1298-1305, 2007. (Pubitemid 46775794)
47. Takigawa Y and Brown AM: Wnt signaling in liver cancer. Curr Drug Targets 9: 1013-1024, 2008.
48. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY and Ng IO: Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 278: 10824-10830, 2003. (Pubitemid 36800356)
49. Durkin EM, Ullmannova V, Guan M and Popescu NC: Deleted in liver cancer 3(DLC-3), a novel RhoGTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene 26: 4580-4589, 2007. (Pubitemid 47037045)
50. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS and Popescu NC: DLC-1: a Rho GTPase-activating protein and tumor suppressor. J Cell Mol Med 11: 1185-1207, 2007. (Pubitemid 350037059)
51. Low JS, Tao Q, Ng KM, Goh HK, Shu XS, Woo WL, Ambinder RF, Srivastava G, Shamay M, Chan AT, Popescu NC and Hsieh WS: A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene 30: 1923-1935, 2011.
52. Liao YC and Lo SH: Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 40: 843-847, 2008.
53. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L and Lowe SW: DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 22: 1439-1444, 2008. (Pubitemid 351793078)
54. Lahoz A and Hall A: DLC1: a significant GAP in the cancer genome. Genes Dev 22: 1724-1730, 2008. (Pubitemid 351915495)
55. Vigil D, Cherfils J, Rossman KL and Der CJ: Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 12: 842-857, 2010.
56. Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS and Popescu NC: DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 579: 1191-1196, 2005. (Pubitemid 40248686)
57. Hers I, Wherlock M, Homma Y, Yagisawa H and Tavaré JM: Identification of p122RhoGAP (deleted in liver cancer-1) Serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells. J Biol Chem 281: 4762-4770, 2006. (Pubitemid 43847737)
58. Murakami R, Osanai T, Tomita H, Sasaki S, Maruyama A, Itoh K, Homma Y and Okumura K: p122 protein enhances intracellular calcium increase to acetylcholine: its possible role in the pathogenesis of coronary spastic angina. Arterioscler Thromb Vasc Biol 30: 1968-1975, 2010.
59. Wu J, Li Y, Fan X, Zhang C, Wang Y and Zhao Z: Analysis of gene expression profile of periodontal ligament cells subjected to cyclic compressive force. DNA Cell Biol 30: 865-873, 2011.
60. Ng IO, Liang ZD, Cao L and Lee TK: DLC1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC1. Cancer Res 60: 6581-6584, 2000.
61. Park SW, Durkin ME, Thorgeirsson SS and Popescu NC: DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma. Int J Oncol 23: 133-137, 2003.
62. Liao YC, Shih YP and Lo SH: Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res 68: 7718-7722, 2008.
63. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE and Kinzler KW: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806, 2008.
64. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B and Iacobuzio- Donahue CA: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117, 2010.
65. Dong X, Zhou G, Zhai Y, Zhang H, Yang H, Zhi L, Zhang X, Chu J and He F: Association of DLC1 gene polymorphism with susceptibility to hepatocellular carcinoma in Chinese hepatitis B virus carriers. Cancer Epidemiol 33: 265-270, 2009.
66. Teodoridis JM, Hardie C and Brown R: CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 268: 177-186, 2008.
67. Yuan BZ, Durkin ME and Popescu NC: Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 140: 113-117, 2003. (Pubitemid 36349010)
68. Wong CM, Lee JM, Ching YP, Jin DY and Ng IO: Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 63: 7646-7651, 2003. (Pubitemid 37466690)
69. Ko FC, Yeung YS, Wong CM, Chan LK, Poon RT, Ng IO and Yam JW: Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. Liver Int 30: 139-148, 2010.
70. Croce MC: Causes and consequences of microRNA dysregulation in cancer. Nature Rev Genet 10: 704-714, 2009.
71. Banaudha K, Kaliszewski M, Korolnek T, Florea L, Yeung ML, Kuan KT and Kumar A: MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 53: 53-61, 2011.
72. Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY and Ng IO: Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 65: 8861-8868, 2005. (Pubitemid 41377375)
73. Healy KD, Hodgson L, Kim TY, Shutes AT, Maddileti S, Juliano RL, Hahn KM, Harden TK, Bang YJ and Der CJ: DLC1 suppresses non-small lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog 47: 326-337, 2008. (Pubitemid 351614573)
74. Kim TY, Lee JW, Kim HP, Jong HS, Kim TY, Jung M and Bang YJ: DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 355: 72-77, 2007. (Pubitemid 46273368)
75. Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG and Lowy DR: Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 104: 9012-9017, 2007. (Pubitemid 47175428)
76. Guan M, Tripathi V, Zhou X and Popescu NC: Adenovirus-mediated restoration of the expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: Prospects for gene therapy. Cancer Gene Ther 15: 371-381, 2008. (Pubitemid 351693225)
77. Zhou X, Zimonjic DB, Park SW, Yang XY, Durkin ME and Popescu NC: DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol 32: 1258-1291, 2008.
78. Holeiter G, Heering J, Erlmann P, Schmid S, Jähne R and Olayioye MA: Deleted in liver cancer 1 controls migration through a Dia1-dependent signaling pathway. Cancer Res 68: 8743-8751, 2008.
79. Erlmann P, Schmid S, Horenkamp FA, Geyer M, Pomorski TG and Olayioye M: DLC1 activation requires lipid interation through a polybasic region preceding the RhoGap domain. Mol Biol Cell 20: 4400-4411, 2009.
80. Zhong D, Zhang J, Yang S, Soh UJ, Buschdorf JP, Zhou YT, Yang D and Low BC: The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci 122: 414-424, 2009.
81. Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142, 2002.
82. Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 27: 602-613, 2005. (Pubitemid 40896091)
83. Jaffe AB and Hall A: Rho GTPases in transformation and metastasis. Adv Cancer Res 84: 57-80, 2002. (Pubitemid 34188194)
84. Ridley AJ: Rho proteins and cancer. Breast Cancer Res Treat 84: 13-19, 2004.
85. Grise F, Bidaud A and Moreau V: Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta 1795: 137-151, 2009.
86. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS and Wang XW: Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology: Dec 24, 2011 (Epub ahead of print).
87. Pihur V, Datta S and Datta S: Finding common genes in multiple cancer types through meta-analysis of microarray experiments: a rank aggregation approach. Genomics 92: 400-403, 2008.
88. Zhou X, Thorgeirsson SS and Popescu NC: Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 23: 1308-1313, 2004. (Pubitemid 38297186)
89. Kawai K, Yamaga M, Iwamae Y, Kiyota M, Kamata H, Hirata H, Homma Y and Yagisawa H: A PLCdelta1-binding protein, p122RhoGAP, is localized in focal adhesions. Biochem Soc Trans 32: 1107-1109, 2004. (Pubitemid 39655559)
90. Kim TY, Vigil D, Der CJ and Juliano RL: Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev 28: 77-83, 2009.
91. Yuan BZ, Jefferson AM, Millecchia L, Popescu NC and Reynolds SH: Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res 313: 3868-3880, 2007. (Pubitemid 47561896)
92. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC and Urquidi V: The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 65: 6042-6053, 2005. (Pubitemid 40994388)
93. Ko FC, Chan LK, Tung EK, Lowe SW, Ng IO and Yam JW: Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology 139: 1397-1407, 2010.
94. Yam JW, Ko FC, Chan CY, Jin DY and Ng IO: Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res 66: 8367-8372, 2006. (Pubitemid 44449146)
95. Liao YC, Si L, deVere White RW and Lo SH: The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol 176: 43-49, 2007. (Pubitemid 46041679)
96. Hall EH, Daugherty AE, Choi CK, Horwitz AF and Brautigan DL: Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion. J Biol Chem 284: 34713-34722, 2009.
97. Chan LK, Ko FC, Ng IO and Yam JW: Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One 4: e5572, 2009.
98. Hafizi S, Sernstad E, Swinny JD, Gomez MF and Dahlbäck B: Individual domains of Tensin2 exhibit distinct subcellular localisations and migratory effects. Int J Biochem Cell Biol 42: 52-61, 2010.
99. Clark K, Howe JD, Pullar CE, Green JA, Artym VV, Yamada KM and Critchley DR: Tensin 2 modulates cell contractility in 3D collagen gels through the RhoGAP DLC1. J Cell Biochem 109: 808-817, 2010.
100. Kawai K, Kitamura SY, Maehira K, Seike J and Yagisawa H: START-GAP1/DLC1 is localized in focal adhesions through interaction with the PTB domain of tensin2. Adv Enzyme Regul 50: 202-215, 2010.
101. Du X, Qian X, Papageorge A, Vass WC, Braverman R and Lowy DR: Complex formation between DLC START domain and Cav1 contributes to the tumor suppressor function of DLC1. Proc Am Assoc Cancer Res 52: 523, 2011.
102. Yang XY, Guan M, Vigil D, Der CJ, Lowy DR and Popescu NC: p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 28: 1401-1409, 2009.
103. Tripathi V, Zimonjic DB and Popescu NC: DLC1 and α-catenin protein interaction enhances DLC1 antioncogenic activity by stabilizing adherens junctions and suppressing NFκB signaling. Proc Am Assoc Cancer Res 52: 962, 2011.
104. Yang X, Popescu NC and Zimonjic DB: DLC1 interaction with S100A10 mediates inhibtion of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-indpendent mechanism. Cancer Res 71: 2916-2925, 2011.
105. Scholz RP, Gustafsson JO, Hoffmann P, Jaiswal M, Ahmadian MR, Eisler S, Erlmann P, Schmid S, Hausser A and Olayioye MA: The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Exp Cell Res 317: 496-503, 2011.
106. Tompa P: Intrinsically unstructured proteins. Trends Biochem Sci 27: 527-533, 2002.
107. Hermeking H: The 14-3-3 cancer connection. Nat Rev Cancer 3: 931-943, 2003.
108. Scholz RP, Regner J, Theil A, Erlmann P, Holeiter G, Jähne R, Schmid S, Hausser A and Olayioye MA: DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J Cell Sci 122: 92-102, 2009.
109. Wuestefeld T and Zender L: DLC1 and liver cancer: the Akt connection. Gastroenterology 139: 1093-1096, 2010.
110. Oliveira AM, Ross JS and Fletcher JA: Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124: S16-S28, 2005.
111. Meyer N and Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990, 2008.
112. Varmus H: Retroviruses. Science 240: 1427-1435, 1988.
113. Peters G: Oncogenes at viral integration sites. Cell Growth Differ 1: 503-510, 1990.
114. Popescu NC and Zimonjic DB: Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med 6: 151-159, 2002. (Pubitemid 44133966)
115. Payne GS, Bishop JM and Varmus HE: Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature 295: 209-214, 1982. (Pubitemid 12138498)
116. Popescu NC, Zimonjic DB and DiPaolo JA: Viral integration, fragile sites and proto-oncogenes in human neoplasia. Hum Genet 84: 383-386, 1990. (Pubitemid 20129478)
117. Liu J, Kaur G, Zhawar VK, Zimonjic DB, Popescu NC, Kandpal R and Athwal RS: Role of SV40 integration site at chromosomal interval 1q21.1 in immortalized CRL2504 cells. Cancer Res 69: 7819-7825, 2009.
118. Weinberg RA: Integrated genomes of animal viruses. Annu Rev Biochem 49: 197-226, 1980.
119. Bester AC, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey- Abina S, Cavazzana-Calvo M, Ben-Porat N, Von Kalle C, Fischer A and Kerem B: Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther 13: 1057-1059, 2006.
120. Croce CM and Nowell PC: Molecular basis of human B cell neoplasia. Blood 65: 1-7, 1985. (Pubitemid 15191031)
121. Zimonjic DB, Keck-Waggoner C and Popescu NC: Novel genomic imbalances and chromosome translocations involving c-myc gene in Burkitt's lymphoma. Leukemia 15: 1582-1588, 2001. (Pubitemid 32994677)
122. Alitalo KM and Schwab M: Oncogene amplification in tumor cells. Adv Cancer Res 47: 235-281, 1986.
123. Alitalo K, Schwab M, Lin CC, Varmus HE and Bishop JM: Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci USA 80: 1707-1711, 1983. (Pubitemid 13136416)
124. Zimonjic DB, Keck-Waggoner CL, Yuan BZ, Kraus MH and Popescu NC: Profile of genetic alterations and tumorigenicity of human breast cancer cells. Int J Oncol 16: 221-230, 2000.
125. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC and Weinberg RA: Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15: 50-65, 2001. (Pubitemid 32060682)
126. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T and Thorgeirsson SS: Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 69: 2775-2782, 2009.
127. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006. (Pubitemid 44286000)
128. Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, Kleeff J, Ehemann V, Eils R, Lichter P, Schirmacher P and Radlwimmer B: Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 47: 511-520, 2008. (Pubitemid 351280719)
129. Wei Y, Ponzetto A, Tiollais P and Buendia MA: Multiple rearrangements and activated expression of c-myc induced by woodchuck hepatitis virus integration in a primary liver tumour. Res Virol 143: 89-96, 1992.
130. Tokino T and Matsubara K: Chromosomal sites for hepatitis B virus integration in human hepatocellu lar carcinoma. J Virol 65: 6761-6764, 1991.
131. Yunis JJ, Soreng AL and Bowe AE: Fragile sites are targets of diverse mutagens and carcinogens. Oncogene 1: 59-69, 1987. (Pubitemid 17149718)
132. Yang L, He J, Chen L and Wang G: Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells. Med Oncol 26: 445-451, 2009.
133. Santoni-Rugiu E, Nagy P, Jensen MR, Factor VM and Thorgeirsson SS: Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor. Am J Pathol 149: 407-428, 1996. (Pubitemid 26256330)
134. Sargent LM, Sanderson ND and Thorgeirsson SS: Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes. Cancer Res 56: 2137-2142, 1996.
135. Factor VM, Laskowska D, Jensen MR, Woitach JT, Popescu NC and Thorgeirsson SS: Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci USA 97: 2196- 2201, 2000.
136. Sargent LM, Zhou X, Keck CL, Sanderson ND, Zimonjic DB, Popescu NC and Thorgeirsson SS: Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Path 154: 1047-1055, 1999. (Pubitemid 29169739)
137. Grisham JW: Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 18: 59-81, 1997.
138. Grisham JW: Molecular genetic alterations in primary hepatocellular meoplasm: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma. In: The Molecular Basis of Human Cancer. Coleman WB and Tsongalis GT (eds). Humana Press, Totowa, New Jersey, NJ, pp259-346, 2001.
139. Durkin ME, Keck-Waggoner CL, Popescu NC and Thorgeirsson SS: Integration of a c-myc transgene results in disruption of the mouse Gtf2ird1 gene, the homologue of the human GTF2IRD1 gene hemizygously deleted in Williams-Beuren syndrome. Genomics 73: 20-27, 2001. (Pubitemid 32382383)
140. Tassabehji M, Hammond P, Karmiloff-Smith A, Thompson P, Thorgeirsson SS, Durkin ME, Popescu NC, Hutton T, Metcalfe K, Rucka A, Stewart H, Read AP, Maconochie M and Donnai D: GTF2IRD1 in craniofacial development of humans and mice. Science 310: 1184-1187, 2005. (Pubitemid 41681744)
141. Zimonjic DB, Ullmannova-Benson V, Factor VM, Thorgeirsson SS and Popescu NC: Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease. Cancer Genet Cytogenet 191: 17-26, 2009.
142. Zimonjic DB, Zhang H, Shan Z, Factor VM, Trent J, Thorgeirsson SS and Popescu NC: DNA amplification associated with double minutes originating from chromosome 19 in mouse hepatocellular carcinoma. Cytogenet Cell Genet 93: 114-116, 2001. (Pubitemid 32727558)
143. Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G and Thorgeirsson SS: Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 53: 1719-1723, 1993. (Pubitemid 23127090)
144. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH and Felsher DW: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117, 2004. (Pubitemid 39472236)
145. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S and Lowe SW: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267, 2006. (Pubitemid 43929093)
146. Roth JA and Grammer SF: Tumor suppressor gene therapy. In: Tumor Supressor Genes: Regulation, Function and Medicinal Applications. El-Deiry WS (ed). Vol. 2. Humana Press, Totowa, NJ, pp577-597, 2003.
147. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heel of cancer. Science 297: 63-64, 2002.
148. Sharma SV and Settleman J: Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231, 2007. (Pubitemid 350277749)
149. Zhang L, Zhang J, Xie L, Xie X, Guo Q, Lv J, Gao Z, Qian Z, Yin X, Zheng L, Zhu G, Ji Q and Ren Z: Molecular characterization of hepatocellular carcinoma (HCC) patient derived explant models. Proc Am Assoc Cancer Res 52: 577, 2011.
150. Wong CC, Wong CM, Au SL and Ng IO: RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N′ Rho move it. Liver Int 30: 642-656, 2010.
151. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H and Hirohashi S: Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 33: 577-581, 2001. (Pubitemid 32185219)
152. Ogawa T, Tashiro H, Miyata Y, Ushitora Y, Fudaba Y, Kobayashi T, Arihiro K, Okajima M and Asahara T: Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant 7: 347-355, 2007. (Pubitemid 46096327)
153. Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, Uehata M, Ohtsuki M, Fujii A, Oshita K, Kataoka H, Chiba K, Goto N and Kondo T: Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol 52: 319-324, 2003. (Pubitemid 37352598)
154. McHenry PR and Vargo-Gogola T: Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment? Curr Drug Targets 11: 1043-1058, 2010.
155. Ullmannova V and Popescu NC: Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Cancer Detect Prev 31: 110-118, 2007. (Pubitemid 46669816)
156. Pang X, Yi T, Yi Z, Cho S G, Qu W, Pinkaew D, Fujise K and Liu M: Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 69: 518-525, 2009.
157. Liu H, Dong A, Gao C, Tan C, Xie Z, Zu X, Qu L and Jiang Y: New synthetic flavone derivatives induce apoptosis of hepatocarcinoma cells. Bioorg Med Chem 18: 6322-6328, 2010.
158. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S and Miwa K: Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639, 2004.
159. Zhou X, Yang XY and Popescu NC: Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. Int J Oncol 36: 999-1005, 2010.
160. Chung GE, Yoon JH, Lee JH, Kim HY, Myung SJ, Yu SJ, Lee SH, Lee SM, Kim YJ and Lee HS: Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncol Rep 25: 1739-1746, 2011.
161. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L and Evan GI: Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14: 447-457, 2008.
162. Larsson LG and Henricksson MA: The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 316: 1429-1437, 2010.
163. Lin CP, Liu CR, Lee CN, Chan TS and Liu HE: Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol 2: 16-20, 2010.
164. Brooks TA and Hurley LH: Targeting MYC expression through G-quardruplexes. Genes Cancer 1: 641-649, 2010.
165. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
166. Llovet J M and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
167. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS and Felsher DW: MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cance Res 71: 2286-2297, 2011.
168. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y and Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001. (Pubitemid 32385829)
169. Homma Y and Emori Y: A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. EMBO J 14: 286-291, 1995.
170. Ponting CP and Aravind L: START: a lipid-binding domain in StAR, HD-ZIP and signalling proteins. Trends Biochem Sci 24: 130-132, 1999. (Pubitemid 29222709)
171. Wang H, Han H, Mousses S and Von Hoff DD: Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol 33: 513-520, 2006. (Pubitemid 44142744)